Heron Therapeutics, Inc. (HRTX) EPS Estimated At $-0.46

Analysts expect Heron Therapeutics, Inc. (NASDAQ:HRTX) to report $-0.46 EPS on May, 9.They anticipate $0.35 EPS change or 43.21 % from last quarter’s $-0.81 EPS. After having $-0.63 EPS previously, Heron Therapeutics, Inc.’s analysts see -26.98 % EPS growth. The stock decreased 4.09% or $1.02 during the last trading session, reaching $23.9. About 1.61 million shares traded or 94.72% up from the average. Heron Therapeutics, Inc. (NASDAQ:HRTX) has risen 35.57% since April 16, 2018 and is uptrending. It has outperformed by 31.20% the S&P500.

Heron Therapeutics, Inc. (NASDAQ:HRTX) Ratings Coverage

Among 3 analysts covering Heron Therapeutics (NASDAQ:HRTX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Heron Therapeutics had 9 analyst reports since February 22, 2019 according to SRatingsIntel. The firm has “Buy” rating given on Monday, March 11 by Cantor Fitzgerald. The firm has “Buy” rating given on Monday, March 11 by Northland Capital. The stock of Heron Therapeutics, Inc. (NASDAQ:HRTX) earned “Buy” rating by Cowen & Co on Friday, February 22. The stock of Heron Therapeutics, Inc. (NASDAQ:HRTX) has “Buy” rating given on Friday, February 22 by Stifel Nicolaus. The rating was maintained by Northland Capital with “Buy” on Monday, February 25. Cantor Fitzgerald maintained Heron Therapeutics, Inc. (NASDAQ:HRTX) rating on Friday, February 22. Cantor Fitzgerald has “Buy” rating and $50 target.

Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company has market cap of $1.87 billion. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single subcutaneous injection. It currently has negative earnings. It offers SUSTOL extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

More notable recent Heron Therapeutics, Inc. (NASDAQ:HRTX) news were published by: Seekingalpha.com which released: “Heron’s Way Ahead: Is There Further Upside? – Seeking Alpha” on August 28, 2018, also Seekingalpha.com with their article: “Heron’s HTX-011 shows treatment benefit in postop pain study; shares up 1% – Seeking Alpha” published on March 11, 2019, Seekingalpha.com published: “Heron Therapeutics provides 2019 outlook – Seeking Alpha” on January 07, 2019. More interesting news about Heron Therapeutics, Inc. (NASDAQ:HRTX) were released by: Prnewswire.com and their article: “Heron Announces European Medicines Agency Validation of Marketing Authorisation Application for HTX-011 for Postoperative Pain Management – PRNewswire” published on April 01, 2019 as well as Seekingalpha.com‘s news article titled: “FDA accepts Heron NDA for non-opioid pain med HTX-011, action date April 30, 2019 – Seeking Alpha” with publication date: December 31, 2018.

Heron Therapeutics, Inc. (NASDAQ:HRTX) Ratings Chart